Tag: Acerus Pharmaceuticals Corporation

December 11, 2018

Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil

Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) is today providing results of a Phase 1 clinical trial (the “trial”)...
November 26, 2018

Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO®

Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) is today providing an update on a number of significant operational and...
October 31, 2018

Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe

Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced the signing of an amendment to its existing licensing and...
October 30, 2018

Acerus Announces Executive Leadership Changes in Corporate Finance

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced that Robert M. Motz will join the Company as Chief...